# The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)

> **NCT01258816** · PHASE1 · COMPLETED · sponsor: **Clavis Pharma** · enrollment: 43 (actual)

## Conditions studied

- Relapsed/Refractory AML

## Interventions

- **DRUG:** Elacytarabine for infusion

## Key facts

- **NCT ID:** NCT01258816
- **Lead sponsor:** Clavis Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2013-05
- **Final completion:** 2013-06
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2013-09-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01258816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01258816, "The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT01258816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*